Collaboration and License Agreements - Additional Information (Details) - USD ($) $ in Thousands		1 Months Ended		3 Months Ended			9 Months Ended
	May 08, 2023	Jul. 31, 2023	Mar. 31, 2020	Sep. 30, 2024	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Collaboration And License Agreements [Line Items]
Collaboration and license revenue				$ 1,049	$ 3,887		$ 2,151	$ 13,838
Long-term deferred revenue				3,676			3,676		$ 5,622
Novartis
Collaboration And License Agreements [Line Items]
License agreement date			Mar. 31, 2020
Collaboration and license revenue						$ 5,800
Amgen Inc. | Amgen Agreement
Collaboration And License Agreements [Line Items]
License agreement date	May 08, 2023
Upfront payment receivable	$ 30,000
Upfront payment received		$ 30,000
Potential milestone payment	$ 500,000
Expects research term	3 years
Collaboration and license revenue				1,000	$ 3,900		2,100	$ 7,000
Deferred revenue				13,600			13,600
Long-term deferred revenue				$ 3,700			$ 3,700